Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Oct 29;8(1):57.
doi: 10.1038/s41387-018-0065-6.

Wdr13 and streptozotocin-induced diabetes

Arun Prakash Mishra  1   2 , Komala Yedella  3 , Jyothi B Lakshmi  3 , Archana B Siva  3
Affiliations

Wdr13 and streptozotocin-induced diabetes

Arun Prakash Mishra et al. Nutr Diabetes. .

Abstract

Type I diabetes, though contributes to only 5-10% of total diabetes cases, is a rising concern in today's world. Our previous studies have shown that the absence of WDR13 in mouse results in pancreatic β-cell hyper-proliferation. Also, amelioration of the diabetic phenotype on introgression of Wdr13-null (Wdr13-/0) mutation in genetically diabetic mice (Leprdb/db) [type II diabetes] was observed. It was thus, interesting to see the role of WDR13 in streptozotocin-mediated diabetes in mice, a model for type I diabetes. Wdr13-/0 mice along with its wild type (Wdr13+/0 mice) littermates were administered streptozotocin intraperitoneally for 5 consecutive days. Blood glucose levels and body weights of these mice were monitored for subsequent 5 weeks and then they were sacrificed for physiological and histological analyses. Results showed that Wdr13-/0 mice exhibited higher serum insulin levels, better glucose clearance and significantly higher number of proliferating β-cells; reiterating the finding that absence of WDR13 helps in β-cell hyper-proliferation and recovery from diabetes; further underscoring WDR13 as a key target molecule for diabetes treatment/amelioration.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
a Weekly blood glucose levels of vehicle and STZ treated Wdr13+/0 and Wdr13-/0 mice. b Gain in body weight of animals treated with vehicle and STZ. c Glucose tolerance test of vehicle treated animals. d Glucose tolerance test of STZ treated animals. e Fasting glucose levels of vehicle and STZ treated animals. f Serum insulin levels of vehicle and STZ treated Wdr13+/0 and Wdr13-/0 mice at the end of the experiment. n = 3 for vehicle treated animals, n = 8 for STZ treated animals. *p < 0.05, ***p < 0.001
Fig. 2
Fig. 2
a Histological analyses of pancreatic sections by hematoxylin-eoisin (H&E) staining, immunostaining with Ki-67 . b Average islet area of vehicle and STZ treated Wdr13+/0 and Wdr13-/0 mice, determined by Axioskop software. c Percentage Ki-67 positive cells in STZ treated Wdr13+/0 and Wdr13-/0 mice. *p < 0.05, **p < 0.01, ***p < 0.001.
See this image and copyright information in PMC

References

    1. Daneman D. Type 1 diabetes. Lancet. 2006;367:847–858. doi: 10.1016/S0140-6736(06)68341-4. - DOI - PubMed
    1. Von Herrath M, Sanda S, Herold K. Type 1 diabetes as a relapsing-remitting disease? Nat. Rev. Immunol. 2007;7:988–994. doi: 10.1038/nri2192. - DOI - PubMed
    1. Van Belle TL, von Herrath MG. Mouse models of type1 diabetes. Drug Discov. Today Dis. Model. 2009;6:41–45. doi: 10.1016/j.ddmod.2009.03.008. - DOI - PMC - PubMed
    1. Chen YC, Colvin ES, Griffin KE, Maier BF, Fueger PT. Mig6 haploinsufficiency protects mice against streptozotocin-induced diabetes. Diabetologia. 2014;57:2066–2075. doi: 10.1007/s00125-014-3311-z. - DOI - PMC - PubMed
    1. Cheng Y, et al. Beta-cell regeneration from vimentin+/MafB+ cells after STZ-induced extreme beta-cell ablation. Sci. Rep. 2015;5:11703. doi: 10.1038/srep11703. - DOI - PMC - PubMed